Auriga Reiterates Hold on Salix Pharmaceuticals (SLXP)
A number of other analysts have also recently weighed in on SLXP. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Salix Pharmaceuticals to $63.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Salix Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, April 20th. They now have a $51.00 price target on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Salix Pharmaceuticals in a research note to investors on Wednesday, April 11st.
Salix Pharmaceuticals traded down 1.53% on Tuesday, hitting $51.32. Salix Pharmaceuticals has a 52-week low of $25.64 and a 52-week high of $53.99. The company has a market cap of $3.035 billion and a price-to-earnings ratio of 33.43.
Salix Pharmaceuticals last posted its quarterly earnings results on Monday, May 7th. The company reported $0.67 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.11. Salix Pharmaceuticals’s revenue was up 61.6% compared to the same quarter last year. Analysts expect that Salix Pharmaceuticals will post $0.68 EPS next quarter.
Salix Pharmaceuticals, Ltd. is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.